Previous 10 | Next 10 |
Market Assessment GlaxoSmithKline plc (GSK) is a large cap ($99B) commercial stage biopharma known for its innovative therapeutics for diverse disease states affecting many organ systems. GSK is not really a household name in reference to therapeutics for viral and non-viral liver diseases...
Introduction CymaBay (CBAY) has been in the news lately for reasons other than the Phase 3 PBC clinical trial. Specifically, the 12-week interim topline data on the effect of seladelpar on relative liver fat reduction was not clinically successful. Unfortunately, these 5 key words " on...
Medivir AB ( OTC:MVRBF ) initiated with Buy rating at H.C. Wainwright. More news on: Medivir AB (publ), Cassava Sciences, Inc., CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
CymaBay Therapeutics (NASDAQ: CBAY ) is up 2.8% after Stifel starts it at Buy in an initiation of companies addressing nonalcoholic fatty liver disease. More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Introduction Albireo ( ALBO ) is one or the only publicly-listed biopharma that has an orphan pediatric cholestatic liver diseases clinical program. Albireo through its unique drug pipeline employs a distinct mechanistic approach to dealing with the distressing adverse event of pruritus (i...
CymaBay Therapeutics ( CBAY ) had a rough day last week when it reported results from its phase 2 study using its drug seladelpar to treat patients with nonalcoholic steatophepatitis (NASH). That's because it was shown that treatment with seladelpar failed to be statistically significa...
CymaBay Therapeutics (NASDAQ: CBAY ) +5.6% pre-market after saying the Food and Drug Administration cleared its Investigational New Drug Application for seladelpar to treat primary sclerosing cholangitis. More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the m...
NEWARK, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced FDA clearance of the company’...
NEWARK, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that Sujal Shah, President and Chie...
Synlogic (NASDAQ: SYBX ) +26% as Ginkgo Bioworks to invest $80M . More news on: Synlogic, Inc., Bridgeline Digital, Inc., MagnaChip Semiconductor Corporation, , Stocks on the move Read more ...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...